Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)

SHE:002365 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	807.85	833.34	959.37	1,426	1,546	1,166
Other Revenue	5.47	5.47	13.52	36.57	19.54	6.87
Revenue	813.32	838.81	972.89	1,462	1,565	1,173
Revenue Growth (YoY)	-5.25%	-13.78%	-33.48%	-6.58%	33.47%	-14.42%
Cost of Revenue	687.05	672.79	722.37	991.13	1,212	820.06
Gross Profit	126.27	166.02	250.52	471.32	353.73	352.8
Selling, General & Admin	73.82	80.61	176.42	249.77	154.58	166.85
Research & Development	35.37	36.97	41.5	40.45	53.04	46.66
Other Operating Expenses	13.17	9.16	10.09	13.66	11.58	10.09
Operating Expenses	118.89	126.05	226.39	301.41	228.94	225.14
Operating Income	7.39	39.97	24.12	169.91	124.79	127.66
Interest Expense	-0.7	-0.59	-0.37	-0.66	-2.44	-1.2
Interest & Investment Income	39.29	40.78	27.39	12.62	24.2	25.99
Currency Exchange Gain (Loss)	9.17	9.17	5.64	21.55	-4.09	-8.54
Other Non Operating Income (Expenses)	-3.65	-1.02	-0.43	-0.64	-0.7	-0.51
EBT Excluding Unusual Items	51.49	88.32	56.35	202.77	141.76	143.39
Impairment of Goodwill	-0.52	-0.52	-8.25	-	-	-
Gain (Loss) on Sale of Investments	-1.06	4.43	-34.55	-30.34	-0.28	-1.19
Gain (Loss) on Sale of Assets	0.25	0.19	45.02	-0.38	0.25	-0.01
Asset Writedown	-15.36	-15.36	-42.06	-3.65	-3.02	-15.45
Legal Settlements	-10.02	-10.02	-23.3	-22.73	-13.61	-4.94
Other Unusual Items	4.46	3.82	12.84	7.4	4.75	8.78
Pretax Income	29.24	70.86	6.05	153.06	129.85	130.58
Income Tax Expense	4.7	11.15	34.47	20.34	10.81	11.92
Earnings From Continuing Operations	24.54	59.71	-28.41	132.72	119.05	118.66
Minority Interest in Earnings	4.18	2.06	16.1	7.63	-7.63	-13.1
Net Income	28.72	61.77	-12.31	140.35	111.42	105.56
Preferred Dividends & Other Adjustments	-	-	-	0.19	3.63	-
Net Income to Common	28.72	61.77	-12.31	140.16	107.78	105.56
Net Income Growth	1974.37%	-	-	25.97%	5.55%	17.38%
Shares Outstanding (Basic)	292	293	295	294	287	288
Shares Outstanding (Diluted)	293	295	295	294	287	289
Shares Change (YoY)	-0.46%	-	0.13%	2.66%	-0.63%	0.06%
EPS (Basic)	0.10	0.21	-0.04	0.48	0.38	0.37
EPS (Diluted)	0.10	0.21	-0.04	0.48	0.38	0.37
EPS Growth	1991.75%	-	-	26.66%	2.75%	17.69%
Free Cash Flow	30.6	-12.33	100.46	238.21	38.76	102.25
Free Cash Flow Per Share	0.10	-0.04	0.34	0.81	0.14	0.35
Dividend Per Share	0.100	0.100	0.100	0.100	-	0.100
Dividend Growth	-	-	-	-	-	-33.33%
Gross Margin	15.53%	19.79%	25.75%	32.23%	22.60%	30.08%
Operating Margin	0.91%	4.76%	2.48%	11.62%	7.97%	10.88%
Profit Margin	3.53%	7.36%	-1.27%	9.58%	6.88%	9.00%
Free Cash Flow Margin	3.76%	-1.47%	10.32%	16.29%	2.48%	8.72%
EBITDA	114.43	152.65	159.3	293.53	240.75	240.72
EBITDA Margin	14.07%	18.20%	16.37%	20.07%	15.38%	20.52%
D&A For EBITDA	107.05	112.68	135.18	123.62	115.96	113.07
EBIT	7.39	39.97	24.12	169.91	124.79	127.66
EBIT Margin	0.91%	4.76%	2.48%	11.62%	7.97%	10.88%
Effective Tax Rate	16.07%	15.74%	569.54%	13.29%	8.32%	9.13%
Revenue as Reported	813.32	838.81	972.89	1,462	1,565	1,173

Source: S&P Global Market Intelligence. Standard template. Financial Sources.